These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8521130)

  • 41. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A; Vaisanen V; Lilja H; Kattan MW; Rittenhouse HG; Pettersson K; Chan DW; Huland H; Sokoll LJ; Partin AW
    J Urol; 2005 Mar; 173(3):752-6. PubMed ID: 15711262
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High-grade prostatic intraepithelial neoplasia in needle biopsy as risk factor for detection of adenocarcinoma: current level of risk in screening population.
    Gokden N; Roehl KA; Catalona WJ; Humphrey PA
    Urology; 2005 Mar; 65(3):538-42. PubMed ID: 15780372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate cancer: A challenge for screening.
    Donnell RF
    Surg Oncol Clin N Am; 1999 Oct; 8(4):693-702, vii. PubMed ID: 10452935
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Screening for prostate cancer: estimating the magnitude of overdetection.
    McGregor M; Hanley JA; Boivin JF; McLean RG
    CMAJ; 1998 Dec; 159(11):1368-72. PubMed ID: 9861205
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Significance of serum free prostate specific antigen in the screening of prostate cancer.
    Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
    J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determining transition probabilities from mortality rates and autopsy findings.
    Black WC; Nease RF; Welch HG
    Med Decis Making; 1997; 17(1):87-93. PubMed ID: 8994155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prevalence of incidental prostate cancer: A systematic review of autopsy studies.
    Bell KJ; Del Mar C; Wright G; Dickinson J; Glasziou P
    Int J Cancer; 2015 Oct; 137(7):1749-57. PubMed ID: 25821151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The contribution of subclinical cancer to Denver's high prostatic cancer incidence rate.
    Beckner M; Berg JW; Franz LW
    J Chronic Dis; 1985; 38(3):225-31. PubMed ID: 3988880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prostate cancer: to screen or not to screen?
    Schröder FH
    BMJ; 1993 Feb; 306(6875):407-8. PubMed ID: 8338522
    [No Abstract]   [Full Text] [Related]  

  • 51. [Comparison of grade of prostate cancer between pretreatment and autopsy].
    Ando K; Fuse H; Shimazaki J; Murakami S; Matsuzaki O
    Nihon Hinyokika Gakkai Zasshi; 1988 Aug; 79(8):1399-405. PubMed ID: 3246826
    [No Abstract]   [Full Text] [Related]  

  • 52. A case of T1C, N3, M1 prostate cancer.
    Pruthi RS; Richman M; Ornstein DK
    Urol Int; 2002; 69(1):82-4. PubMed ID: 12119447
    [No Abstract]   [Full Text] [Related]  

  • 53. Prostatic carcinoma. An autopsy study.
    Lundberg S; Berge T
    Scand J Urol Nephrol; 1970; 4(2):93-7. PubMed ID: 5518094
    [No Abstract]   [Full Text] [Related]  

  • 54. Words of wisdom. Re: Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence.
    Roemeling S; Schröder FH
    Eur Urol; 2008 Mar; 53(3):663-4. PubMed ID: 18363207
    [No Abstract]   [Full Text] [Related]  

  • 55. Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
    Haese A; Graefen M; Huland H; Lilja H
    Curr Urol Rep; 2004 Jun; 5(3):231-40. PubMed ID: 15161573
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are T1c tumors different from incidental tumors found at autopsy? The risk and reality of overdetection.
    Belville WD
    Semin Urol Oncol; 1995 Aug; 13(3):181-6. PubMed ID: 8521130
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era.
    Konety BR; Bird VY; Deorah S; Dahmoush L
    J Urol; 2005 Nov; 174(5):1785-8; discussion 1788. PubMed ID: 16217287
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The independent impact of extended pattern biopsy on prostate cancer stage migration.
    Master VA; Chi T; Simko JP; Weinberg V; Carroll PR
    J Urol; 2005 Nov; 174(5):1789-93; discussion 1793. PubMed ID: 16217288
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate biopsy: who, how and when. An update.
    Djavan B; Milani S; Remzi M
    Can J Urol; 2005 Feb; 12 Suppl 1():44-8; discussion 99-100. PubMed ID: 15780165
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.